SenesTech, Inc. Q3 FY2024 earnings call

• Evolve Rat, launched less than a year ago, has grown from zero revenue to 52% of business. • Q3 2024 gross margins were 65%, a significant increase from prior quarters. • Operating expenses down 12% YOY due to revenue growth and efficient selling processes. • Adjusted EBITDA was best quarterly performance in company history, 21% improvement YOY. • Introduced mouse product in May 2024, contributing 17% of Q3 revenue. • Expansion with online retailers: Amazon 43% of e-commerce, launched on Walmart.com, testing TractorSupply.com. • Brick-and-mortar retail: working with rep agencies, exhibiting at buying shows. • Municipal programs: NYC rat contraception pilot program, submitted supply proposal. • Global expansion: received multi-pallet order from Netherlands, full registration in Hong Kong, progressing in Australia, New Zealand, India, etc. • Packaging: new pouches using 87% less plastic, enhancing margins. • Studies underway: trials with agricultural firm, pest management company, university. • Regulatory: Evolve Rat available in 47 states, Evolve Mouse in 35 states.

During Q3 2024, Evolve Rat accounted for 52% of revenue. Evolve Mouse, launched in May 2024, represented 17% of Q3 revenue. ContraPest and related products made up the remaining 31% of revenue. Gross margins were a record 65% in Q3 2024, up from 49% in Q3 2023 and 54% in Q2 2024.

• Anticipates cash flow breakeven next year. • Potential for growth from global push and new products.

Q: Can you talk about the timing as it relates to when you think you might hear from New York City?

A: Yes, it should be soon. We have been going back and forth on a few things, and it will certainly be within the next month.